Zanubrutinib may produce superior outcomes to ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Lenalidomide increases the risk of developing a second primary malignancy in patients with multiple myeloma, a meta-analysis suggests.
Patients with chronic lymphocytic leukemia or monoclonal B-cell lymphocytosis have an increased risk of venous thromboembolism, a study suggests.
The incidence of cutaneous adverse events in cancer patients receiving PI3K inhibitors may be as high as 29%, a meta-analysis suggests.
Researchers evaluated the anti-spike T-cell and antibody responses to SARS-CoV-2 mRNA vaccines in patients with B-cell malignancies in a real-world setting.
Researchers sought to compare zanubrutinib with ibrutinib in patients with CLL/SLL.
Combination acalabrutinib, obinutuzumab, and venetoclax did not meet the prespecified activity threshold in the CLL2-BAAG trial.
Researchers sought to determine the long-term clinical experience of patients with HCL treated with frontline cladribine.
The approval was based on data from the phase 1 ELEVATE-PLUS trials, which showed that acalabrutinib 100 mg tablets were bioequivalent to the acalabrutinib 100 mg capsules.
Zanubrutinib can improve progression-free survival, when compared with bendamustine-rituximab, in previously untreated CLL/SLL, a phase 3 trial suggests.
The FDA recommends that health care providers evaluate the risks and benefits of continuing Copiktra vs prescribing an alternative therapy.
Patients with previously untreated CLL had superior PFS with fixed duration venetoclax plus obinutuzumab, with or without ibrutinib.
Researchers sought to determine the case fatality rate in patients with CLL who were infected with SARS-CoV-2.
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of the Bence-Jones protein.
Of the NHL patients with neutralizing antibodies against the WA1/2020 SARS-CoV-2 strain, 70% had antibodies against the delta variant, and 33% had antibodies against the omicron variant.
TG Therapeutics has decided to take Ukoniq (umbralisib) off the market and withdraw pending applications for the drug.
Patients with CLL were significantly more likely to have an antibody response to the Moderna vaccine than to the Pfizer-BioNTech vaccine.
Researchers sought to determine whether adding venetoclax to R-EPOCH would induce durable responses in patients with Richter syndrome.
Response rates improved from 2000 to 2019, but the rate of treatment-related fatal toxicities remained stable.
An initial review of data from the phase 3 UNITY trial in CLL patients showed the combination of Ukoniq and ublituximab was associated with increased risk of death compared with the control arm.